Amylyx Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO (sodium phenylbutyrate and taurursodiol) for the treatment of adults with amyotrophic lateral sclerosis (ALS). RELYVRIO (previously known as AMX0035 in the U.S.) significantly slowed the loss of physical function in people living with ALS in a randomized, placebo-controlled clinical trial. RELYVRIO can be taken as a monotherapy or with existing approved treatments.
- Read more about Amylyx Pharmaceuticals announces FDA approval of RELYVRIO for the Treatment of ALS
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/amylyx-pharmaceuticals-announces-fda-approval-of-relyvrio-for-the-treatment-of-als
No comments:
Post a Comment